Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Isopropyl Alcohol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isopropyl Alcohol SCHEMBL3840021 | 1.00 | — | — | |
| Isopropyl Alcohol SCHEMBL333531 | 0.96 | — | — | |
| Isopropyl Alcohol SCHEMBL367599 | 0.96 | — | — | |
| Isopropyl Alcohol SCHEMBL28259581 | 0.92 | — | — | |
| Isopropyl Alcohol SCHEMBL3892643 | 0.92 | — | — | |
| Isopropylamine SCHEMBL910615 | 0.89 | ALDH1A1 (0.40) | ALDH1A1LMNATSHR | |
| Isopropyl Alcohol SCHEMBL7065604 | 0.88 | — | — | |
| Isopropyl Alcohol SCHEMBL5930753 | 0.88 | ALDH1A1 (0.46) | ALDH1A1LMNATSHR | |
| Isopropyl Alcohol SCHEMBL6009460 | 0.87 | TSHR (0.38) | ALDH1A1LMNATSHR | |
| Isopropyl Alcohol SCHEMBL10462689 | 0.85 | ALDH1A1 (0.43) | ALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117269402-B | Liquid phase mass spectrum combination method for quantitatively detecting norcinnabar in human cerebrospinal fluid | 中国医学科学院北京协和医院 | 2024-02-23 | — | — | CN | claimed |
| CN-117250301-B | Liquid phase mass spectrum combined method for quantitatively detecting norcinnabar in human plasma | 中国医学科学院北京协和医院 | 2024-02-09 | — | — | CN | claimed |
| CN-117269402-A | Liquid phase mass spectrum combination method for quantitatively detecting norcinnabar in human cerebrospinal fluid | 中国医学科学院北京协和医院 | 2023-12-22 | — | — | CN | claimed |
| CN-117250301-A | Liquid phase mass spectrum combined method for quantitatively detecting norcinnabar in human plasma | 中国医学科学院北京协和医院 | 2023-12-19 | — | — | CN | claimed |
| US-10849934-B2 | Compound and preparation method thereof | GUANGXI JIUFU BIOTECHNOLOGY CO., LTD (CN) | 2020-12-01 | — | — | US | claimed |
| US-20200199144-A1 | Compound and Preparation Method Thereof | GUANGXI JIUFU BIOTECHNOLOGY CO., LTD (CN) | 2020-06-25 | — | — | US | claimed |
| CN-104237407-A | Method for detecting releasing rate of amantadine hydrochloride sustained release tablets | SHANDONG INST PHARMACEUTICAL INDUSTRY | 2014-12-24 | — | — | CN | claimed |
| US-12023407-B2 | Artificial exosome composition and related methods | UNIVERSITY OF MASSACHUSETTS (US) | 2024-07-02 | — | — | US | disclosed |
| US-11925665-B2 | Extract effective in treating drug addiction | GUANGXI JIUFU BIOTECHNOLOGY CO., LTD (CN) | 2024-03-12 | — | — | US | disclosed |
| CN-117269402-B | Liquid phase mass spectrum combination method for quantitatively detecting norcinnabar in human cerebrospinal fluid | 中国医学科学院北京协和医院 | 2024-02-23 | — | — | CN | disclosed |
| CN-117250301-B | Liquid phase mass spectrum combined method for quantitatively detecting norcinnabar in human plasma | 中国医学科学院北京协和医院 | 2024-02-09 | — | — | CN | disclosed |
| CN-117269402-A | Liquid phase mass spectrum combination method for quantitatively detecting norcinnabar in human cerebrospinal fluid | 中国医学科学院北京协和医院 | 2023-12-22 | — | — | CN | disclosed |
| CN-117250301-A | Liquid phase mass spectrum combined method for quantitatively detecting norcinnabar in human plasma | 中国医学科学院北京协和医院 | 2023-12-19 | — | — | CN | disclosed |
| US-20140349967-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2014-11-27 | — | — | US | disclosed |
| US-8471025-B2 | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2013-06-25 | — | — | US | disclosed |
| US-20110152311-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | FOREST LABORATORIES HOLDINGS LTD. (BM) | 2011-06-23 | — | — | US | disclosed |
| US-20090269832-A1 | Growth of Microorganisms in Media Containing Crude Glycerol | MODULAR GENETICS, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| EP-1047438-B1 | A PROCESS FOR THE ISOLATION, RECOVERY AND PURIFICATION OF NON-POLAR EXTRACTIVES | CA MINISTER AGRICULTURE & FOOD (CA) | 2004-09-08 | — | — | EP | disclosed |
| US-6495140-B1 | SOLVENT EXTRACTION OF SYNTHETIC AND PLANT EXTRACTS, SEPARATING USING POLYSACCHARIDE GEL MATRICES, THEN REGENERATING THE GELS BY WASHING FOR REUSE | HER MAJESTY IN RIGHT OF CANADA AS REPRESENTED BY THE MINISTER OF AGRICULTURE AND AGRI-FOOD CANADA (CA) | 2002-12-17 | — | — | US | disclosed |
| US-5719195-A | Treatment of psoriasis with 11-cis-retinoic acid | 4 THOUGHT TECHNOLOGIES (US) | 1998-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152311-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | SLC10A6, SLC5A2, SLC5A1 | ALDH1A1 4203/4885LMNA 3412/4885TSHR 772/4885 |
| US-11925665-B2 | Extract effective in treating drug addiction | NR1H3, CYP46A1, GRIN3A | ALDH1A1 317/4885LMNA 4446/4885TSHR 2294/4885 |
| US-20200199144-A1 | Compound and Preparation Method Thereof | CYP2E1, CYP1A2, CYP4X1 | ALDH1A1 132/4885LMNA 958/4885TSHR 3537/4885 |
| US-20140349967-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | SLC10A6, SLC5A2, SLC5A1 | ALDH1A1 4203/4885LMNA 3412/4885TSHR 772/4885 |
| US-10849934-B2 | Compound and preparation method thereof | CYP2E1, CYP1A2, CYP4X1 | ALDH1A1 132/4885LMNA 958/4885TSHR 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.